Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes

被引:364
作者
Ishida, Tatsuhiro [1 ]
Kiwada, Hiroshi [1 ]
机构
[1] Univ Tokushima, Inst Hlth Biosci, Subdiv Biopharmaceut Sci, Dept Pharmacokinet & Biopharmaceut, Tokushima 7708505, Japan
关键词
IgM; polyethylene glycol (PEG); accelerated blood clearance (ABC) phenomenon; liposomes; repeated injection; complement activation;
D O I
10.1016/j.ijpharm.2007.11.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We and a Dutch group reported that "empty" PEGylated liposomes (approximately 100 nm) lose their long-circulating characteristic when they are administrated twice in the same animal with certain intervals (referred to as the accelerated blood clearance (ABC) phenomenon). Very recently, we showed that anti-PEG IgM, induced by the first dose of "empty" PEGylated liposomes, is responsible for inducing the phenomenon, based on the observation that IgM thus produced selectively binds to the surface of subsequently injected PEGylated liposomes, leading to substantial complement activation. It is generally believed that nanocarriers coated with a polymer, such as PEG, have no or lower immunagenicity. However, the results indicated evidence that unexpected immune responses occur even to such polymer-coated liposomes. Such immunogenicity of "empty" liposomes presents a serious concern in the development of liposomal formulations and their use in the clinic. In addition, through series of our studies, it was demonstrated that the magnitude of the ABC phenomenon depends on the physicochemical property of injected liposomes as a first dose, time interval between injection, lipid dose and drug-encapsulation. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 62
页数:7
相关论文
共 60 条
[1]   UPTAKE OF LIPOSOMES BY CULTURED MOUSE BONE-MARROW MACROPHAGES - INFLUENCE OF LIPOSOME COMPOSITION AND SIZE [J].
ALLEN, TM ;
AUSTIN, GA ;
CHONN, A ;
LIN, L ;
LEE, KC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1061 (01) :56-64
[2]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[3]   LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :91-97
[4]   Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer [J].
Bourgeois, Hugues ;
Ferru, Aurelie ;
Lortholary, Alain ;
Delozier, Thierry ;
Boisdron-Celle, Michelle ;
Abadie-Lacourtoisie, Sophie ;
Joly, Florence ;
Chieze, Stephanie ;
Chabrun, Virginie ;
Gamelin, Erick ;
Tourani, Jean-Marc .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (03) :267-275
[5]   Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours [J].
Caraglia, M ;
Addeo, R ;
Costanzo, R ;
Montella, L ;
Faiola, V ;
Marra, M ;
Abbruzzese, A ;
Palmieri, G ;
Budillon, A ;
Grillone, F ;
Venuta, S ;
Tagliaferri, P ;
Del Prete, S .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) :34-39
[6]   Prevention of protein adsorption by flexible and rigid chain molecules [J].
Carignano, MA ;
Szleifer, I .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2000, 18 (3-4) :169-182
[7]   Phase II trial of liposomal doxorubicin (Doxil®) in advanced soft tissue sarcomas [J].
Chidiac, T ;
Budd, GT ;
Pelley, R ;
Sandstrom, K ;
McLain, D ;
Elson, P ;
Crownover, R ;
Marks, K ;
Muschler, G ;
Joyce, M ;
Zehr, R ;
Bukowski, R .
INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) :253-259
[8]  
CHONN A, 1992, J BIOL CHEM, V267, P18759
[9]   A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993) [J].
Coleman, RE ;
Biganzoli, L ;
Canney, P ;
Dirix, L ;
Mauriac, L ;
Chollet, P ;
Batter, V ;
Ngalula-Kabanga, E ;
Dittrich, C ;
Piccart, M .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) :882-887
[10]  
Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071